Quality of life predicts outcome of deep brain stimulation in early Parkinson disease
العنوان: | Quality of life predicts outcome of deep brain stimulation in early Parkinson disease |
---|---|
المؤلفون: | Stéphane Thobois, Marie Vidailhet, Stéphane Derrey, Andrea Kistner, Philippe Damier, Daniel Weiss, W.M. Michael Schuepbach, Günther Deuschl, Thomas D. Hälbig, Tobias Wächter, Andreas Kupsch, Michael T. Barbe, Jan Vesper, Carmen Schade-Brittinger, Christine Brefel-Courbon, G.R. Fink, Jean-Luc Houeto, Friederike Sixel-Döring, Alireza Gharabaghi, Jens Volkmann, Karina Knudsen, David Maltête, Andrea A. Kühn, Andrea Falk, Patrick Mertens, Gerd-H. Schneider, Lars Timmermann, Alfons Schnitzler, Eric Seigneuret, Fabienne Ory-Magne, Pascal Derkinderen, Patrick Chaynes, Tatiana Witjas, Joern Rau, Valérie Fraix, S. Paschen, J. Regis, Lisa Tonder, Lars Wojtecki, Marcus O. Pinsker, Paul Krack, Haidar S. Dafsari, Andreas Hartmann, Fanny Pineau, Laura Paschen, Claudia Trenkwalder, Yves Agid |
المساهمون: | Universität Bern [Bern] (UNIBE), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), CIC AP-HP (pitie-Salpetriere)/inserm, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Medtronic [Minneapolis, MI, USA], Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], University of Geneva [Switzerland], Centre de coordination des essais cliniques, Philipps-University, Marburg, Allemagne., Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] (CIC Neurosciences), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), NeuroCure Clinical Research Center (NCRC), Charité University Medical Center, Charité (Campus Mitte), Berlin, Germany., Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Department of Neuroscience, Karolinska institutet, Stockholm, Sweden, Department of Neuroscience, Karolinska institutet, Department of Neurology, University Medical Center Schleswig-Holstein, Arnold-Heller-Street 3, Kiel 24105, Germany., Department of Neurology, Christian-Albrechts-University, Kiel, Germany., Christian-Albrechts-Universität zu Kiel (CAU), University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany., National Parkinson Foundation Centre of Excellence, King's College Hospital, London, UK., Department of Neurology, University of Cologne, Cologne, Germany., Department of Neurology, Movement Disorder and Neuromodulation Unit, Charité-Universitätsmedizin, Berlin, Germany., NeuroCure Clinical Research Center, Charité-Universitätsmedizin, Berlin, Germany., Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Department of Neurology & Neurosurgery, Charite University Medicine Berlin, Campus Virchow Klinikum & Benjamin Franklin, Berlin, Germany., Centre Hospitalier Universitaire [Grenoble] (CHU), Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), UM des troubles du mouvement, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service d'Anatomie et Cytopathologie [Toulouse], Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique de Toulouse (CIC 1436), Department of Functional Neurosurgery and Stereotaxy, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany., Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de neurologie [Rouen], Normandie Université (NU)-Normandie Université (NU), Clinique neurologique, Hôpital Laennec, Neuropathies du système nerveux entérique et pathologies digestives, implication des cellules gliales entériques, Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), Paracelsus-Elena-Klinik, Kassel, Germany., Department of Neurology, Philipps University Marburg, Germany., Paracelsus Elena Klinik, Centre for Parkinson's Disease & Movement Disorders, Department of Neurosurgery, University of Tuebingen, Center of Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, University of Vermont [Burlington], Stereotactic and Functional Neurosurgery Service and Gamma Knife Unit CHU Timone Marseille, France., AP-HM, CHU Timone, Pole de Neurosciences Cliniques, Department of Neurology, Marseille, France., Service de Neurologie, Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service Public de Wallonie, Department of Nuclear Medicine and PET Centre Aarhus University Hospital, Institute of Clinical Medicine Aarhus University, Norrebrogade 44, Building 10, 8000, Aarhus C, Denmark., Somnomar, Sleep Research Institute, Service de neurologie [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neurologie et thérapeutique expérimentale, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Heinrich-Heine-Universität Düsseldorf [Düsseldorf], Département de Neurologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-IFR70-CHU Pitié-Salpêtrière [APHP], Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Toulouse, Service de Pharmacologie Médicale et Clinique, CHU Toulouse [Toulouse], University of Vermont College of Medicine [Burlington, VT, USA], Laboratoire de Neurosciences Cognitives [Marseille] (LNC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR70-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Universität Bern [Bern], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Charité Hospital, Humboldt Universität zu Berlin, Service de neurochirurgie [Rouen] |
المصدر: | Neurology Neurology, American Academy of Neurology, 2019, 92 (10), pp.e1109-e1120. ⟨10.1212/WNL.0000000000007037⟩ Neurology 92(10), e1109 (2019). doi:10.1212/WNL.0000000000007037 Schüpbach, Michael; Tonder, Lisa; Schnitzler, Alfons; Krack, Paul; Rau, Joern; Hartmann, Andreas; Hälbig, Thomas D; Pineau, Fanny; Falk, Andrea; Paschen, Laura; Paschen, Stephen; Volkmann, Jens; Dafsari, Haidar S; Barbe, Michael T; Fink, Gereon R; Kühn, Andrea; Kupsch, Andreas; Schneider, Gerd-H; Seigneuret, Eric; Fraix, Valerie; ... (2019). Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology, 92(10), e1109-e1120. American Academy of Neurology 10.1212/WNL.0000000000007037 <http://dx.doi.org/10.1212/WNL.0000000000007037> |
بيانات النشر: | HAL CCSD, 2019. |
سنة النشر: | 2019 |
مصطلحات موضوعية: | 0301 basic medicine, medicine.medical_specialty, Parkinson's disease, Deep brain stimulation, medicine.medical_treatment, 610 Medicine & health, Disease, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Quality of life, Rating scale, law, Internal medicine, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Clinical endpoint, Medicine, ddc:610, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], 10. No inequality, ComputingMilieux_MISCELLANEOUS, business.industry, medicine.disease, humanities, 3. Good health, nervous system diseases, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], Subthalamic nucleus, 030104 developmental biology, Neurology (clinical), business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, 030217 neurology & neurosurgery |
الوصف: | ObjectiveTo investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications.MethodsWe performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson’s Disease Rating Scale (UPDRS) (UPDRS-III “off” and “on” medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI.ResultsPDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups (p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group.ConclusionImpaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS.Clinicaltrials.gov identifierNCT00354133. |
وصف الملف: | application/pdf |
اللغة: | English |
تدمد: | 0028-3878 1526-632X |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b969db51fa582ea76be80aafe3e5ac17 https://hal-normandie-univ.archives-ouvertes.fr/hal-02373051 |
حقوق: | OPEN |
رقم الأكسشن: | edsair.doi.dedup.....b969db51fa582ea76be80aafe3e5ac17 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 00283878 1526632X |
---|